• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study: Retina a potential biomarker for reduced brain matter


Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.

Researchers from the Department of Ophthalmology at the University Hospital Bonn (UKB) and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) have found a close connection between the dimensions of retinal structures and those of the brain.

They report on this in the journal Scientific Reports1. The investigators’ study results suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy”. The findings are based on data from the so-called Rhineland Study.

Within the framework of the Rhineland Study – a large-scale population study in the Bonn city area – DZNE is researching key factors for a healthy life. Determining biomarkers for dementia and other neurodegenerative diseases is one of the study’s goals. One focus is on the human retina, for which the DZNE closely cooperates with the Department of Ophthalmology of UKB.

Frank G. Holz, director of the Department of Ophthalmology of UKB,noted that there is evidence that the retina can serve as a window into the brain.

“Our current results support this view,” Holz said in a statement. “Compared to earlier studies, we used more advanced technology and investigated a larger group of people.”

State-of-the-art imaging in the Rhineland Study

The DZNE news release noted that in almost 3000 participants of the Rhineland Study aged between 30 and 94 years, the retina was assessed using “spectral domain optical coherence tomography” (SD-OCT) – a technique that provides detailed images of the retina and its various layers. In addition, brain scans were performed by magnetic resonance imaging (MRI). The data were analyzed using sophisticated software algorithms. “This allowed for automated identification and determination of thickness and volumes, of both the different retinal layers and the different structures of the brain. Next, we looked for associations between the volume of the retina and the volume of certain brain structures,” Matthias M. Mauschitz, MD, PhD, resident at UKB’s Department of Ophthalmology, postdoctoral scientist at DZNE and first author of the current publication, said in a statement.

Thinner retinal layers along with reduced brain volume

“There was a close relation between layers of the inner retina and the so-called white matter in the brain,” Mauschitz explained. “The thinner these retinal layers, the smaller the volume of the brain’s white matter.”

By contrast, sections of the outer retina were mainly associated with the gray matter of the cerebral cortex. In the brain’s occipital lobe, where visual processing happens, these associations were particularly pronounced. And the researchers found further relationships.

“Interestingly, the thickness of different retinal layers correlated closely with the volume of the hippocampus. This is an area of the brain that plays a central role in memory and is often affected in dementia,” Robert P. Finger, MD, PhD, senior ophthalmologist at the UKB’s Department of Ophthalmology, said in a statement.

Progression monitoring in neurodegenerative diseases?

“Imaging of the retina using SD-OCT is relatively simple, non-invasive and inexpensive. The current results suggest that SD-OCT measurements of the retina could potentially serve as biomarkers for brain atrophy and to monitor progression of certain neurodegenerative diseases,” Monique M. B. Breteler, MD, PhD, director of Population Health Sciences at DZNE and head of the Rhineland Study, said in a news release. “Further population-based studies as well as studies in patient groups and over a longer period of time are now needed to verify these results in a clinical setting.”

Mauschitz, M.M., Lohner, V., Koch, A. et al. Retinal layer assessments as potential biomarkers for brain atrophy in the Rhineland Study. Sci Rep 12, 2757 (2022). https://doi.org/10.1038/s41598-022-06821-4
Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Kelsey Roelofs, MD, details collaborative strategies for the management of thyroid eye disease
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
© 2024 MJH Life Sciences

All rights reserved.